TP53 p.Arg181 modifications in cancer-cell lines and mouse models have shown to be able to activate p21CDKN1A or MDM2 at levels similar to wild-type TP53, but unable to activate genes associated with apoptosis, such as NOXA or p53AIP1 [44, 45]. This evidence concerns the gene MDM2 and cancer.